In Reply.---
We appreciate the letter submitted by Drs. Rowley and Shulman
regarding our article on adenoviral infections in children (1) and
the opportunity to discuss some of the important issues related to
adenovirus (ADV) infection and suspected Kawasaki disease
(KD).
Drs. Rowley and Shulman point out that asymptomatic shedding of
adenoviruses may occur following primary infection, especially
with adenovirus type 1 or 2 acquired in the first year of life. (2, 3)
We are aware of this data. We would point out, however, that at
this time there are 49 distinct types of ADV recognized in humans.
Infection in susceptible hosts may occur at any time and
community outbreaks of ADV infection occur. (4-6) In the 1977
study mentioned by Drs Rowley and Shulman, JP Fox and
colleagues noted that in susceptible subjects with respiratory
shedding of ADV, 65% were clinically ill and the majority of illness
was febrile. (3) In the Fox studies, detection of ADV was done by
viral culture. (3) This method is known to be more sensitive than
direct fluorescent assay (DFA) used in our study. (7) It is possible
that respiratory shedding detected by DFA may be more likely to
be related to acute illness with high viral loads than shedding
detected by culture.
Drs. Rowley and Shulman express concern that we did not confirm
ADV infections in study subjects with serology. We would remind
them that this was a retrospective study and that we did not have
access to acute and convalescent serum samples. Even if
serologic testing had been possible, interpretation of results may
be difficult. The 49 known ADV types are immunologically distinct
and are categorized into 4 subgroups. However, heterotypic
antibody responses may occur for adenoviruses within the same
subgroup and caution is needed in interpreting type specific
antibody results. (8) The sensitivity of complement fixation tests,
the most widely available, is low and more sensitive tests are not
standardized for commercial use. (8) Finally in the acute setting,
serology is unlikely to be useful in helping to establish whether a
febrile episode is related to ADV or not, since 2 specimens
obtained 2-4 weeks apart are needed to confirm diagnosis.
Regarding platelet counts in the patients presented, the authors
are well aware that many inflammatory conditions, including
infectious diseases may elevate platelet counts. In our study, 35%
of children who were diagnosed with ADV infection and in whom
there was no suspicion of KD had platelet counts over 400,000
mm3 and 18% had platelet counts over 500,00 mm3.
The most important concern expressed by Drs. Rowley and
Shulman is the possibility of children with KD being misdiagnosed
as having adenoviral infection if asymptomatic shedding of ADV
was occurring. We share this concern and take it seriously. We
performed a review of the literature prior to publication of our study
to try and find any evidence of ADV infection and KD occurring
simultaneously and could find only 1 report where the possibility of
both entities was considered to be possible. (9) We believe more
study is needed in this area.
In the US, where measles immunization is nearly universal, the
most common viral mimic of KD will likely be ADV infection. The
use of DFA testing, which can yield results quickly (4 hours in our
institution), compared to culture (9 days), or serologic testing (>
4weeks) can provide information that can be used to inform the
differential diagnosis of the patient. (1, 10)
We have used DFA testing for the last 4 years to perform viral
surveillance in our community.(11) This has been the gold-
standard in pediatrics for recognizing respiratory syncytial virus
(RSV) season. By using a DFA that tests for multiple common
respiratory viruses, we have been able to track not only RSV, but
also influenza, parainfluenza, and adenovirus in our community.
Four out of five of the patients we presented with suspected KD
and a positive DFA for ADV were diagnosed between January and
April of 2002, during a peak in ADV activity in our community. (1)
DFA testing should be used in context with the patient’s clinical
presentation, contacts, viral activity in the community, etc. to help
the physician decide whether KD is the most likely diagnosis.
Obviously, if KD cannot be excluded, treatment should be initiated.
In a separate article, Dr. Rowley notes that the overdiagnosis of
KD seems less harmful than under-diagnosis. (12) This may be
correct, but as we pointed out in our paper, the treatment of KD is
not without risk (13-16) and the overdiagnosis may be associated
with long term consequences such as lower perceived health,
parental anxiety and the vulnerable child syndrome. (17) As
physicians, we must do all that we can to assure the diagnosis of
KD is correct. The DFA test for ADV provides a timely piece of
information that can be added to the decision-making process.
Finally, we would like to comment on the area of KD research. We
believe that it is critical that prospective research studies be
performed that can address the issues of ADV as a mimic of KD.
As we stated in our article, “ the prospective study of ADV infection
in children with suspected KD could help clarify important issues
such as how often ADV and KD occur together, whether
asymptomatic shedding of ADV occurs in children with KD, and
which serotypes of ADV mimic KD.” A review of recent large
studies of children with diagnosed KD, including studies by Drs.
Rowley and Shulman, all include the specific clinical criteria used
to diagnose KD, but none mentions standard testing of children to
exclude those with possible bacterial or viral infections. (18-22) A
large study performed in 1991 that examined mimics of KD, noted
that in nearly 50% of patients with suspected KD, but with another
diagnosis established, fulfilled all standard diagnostic criteria for
KD. (23) Our understanding of KD, especially in children without
coronary artery involvement may be jeopardized if children with
ADV infection are inadvertently included in the study populations.
We stand by our conclusion that all children with suspected KD in
the US be tested for ADV infection.
Sincerely,
Carrie L. Byington, MD
Associate Professor of Pediatrics and Infectious Diseases
University of Utah
Christian Rocholl, MD
Fellow in Pediatric Emergency Medicine
Brown University
References
1. Rocholl C, Gerber K, Daly J, Pavia AT, Byington CL. Adenoviral
infections in children: the impact of rapid diagnosis. Pediatrics. Jan
2004;113(1 Pt 1):e51-56.
2. Fox JP, Brandt CD, Wassermann FE, et al. The virus watch
program: a continuing surveillance of viral infections in
metropolitan New York families. VI. Observations of adenovirus
infections: virus excretion patterns, antibody response, efficiency of
surveillance, patterns of infections, and relation to illness. Am J
Epidemiol. Jan 1969;89(1):25-50.
3. Fox JP, Hall CE, Cooney MK. The Seattle Virus Watch. VII.
Observations of adenovirus infections. Am J Epidemiol. Apr
1977;105(4):362-386.
4. Hong JY, Lee HJ, Piedra PA, et al. Lower respiratory tract
infections due to adenovirus in hospitalized Korean children:
epidemiology, clinical features, and prognosis. Clin Infect Dis.
2001;32(10):1423-1429.
5. Two fatal cases of adenovirus-related illness in previously
healthy young adults--Illinois, 2000. MMWR Morb Mortal Wkly
Rep. 2001;50(26):553-555.
6. Civilian outbreak of adenovirus acute respiratory disease--
South Dakota, 1997. MMWR Morb Mortal Wkly Rep.
1998;47(27):567-570.
7. Cherry JD. Adenoviruses. In: Feigin R, Cherry J, Demmler G,
Kaplan S, eds. Textbook of Pediatric Infectious Diseases. Vol 2.
Philadelphia: Saunders; 2004:1843-1863.
8. Demmler GJ. Adenoviruses. In: Long S, Pickering L, Prober C,
eds. Principles and Practice of Pediatric Infectious Diseases. New
York: Churchill Livingstone; 2003:1076-1080.
9. Embil JA, McFarlane ES, Murphy DM, Krause VW, Stewart HB.
Adenovirus type 2 isolated from a patient with fatal Kawasaki
disease. Can Med Assoc J. 1985;132(12):1400.
10. Barone SR, Pontrelli LR, Krilov LR. The differentiation of
classic Kawasaki disease, atypical Kawasaki disease, and acute
adenoviral infection: use of clinical features and a rapid direct
fluorescent antigen test. Arch Pediatr Adolesc Med.
2000;154(5):453-456.
11. Daly J, Gerber K, Pavia AT. Viral Surveillance at Primary
Childrens Medical Center. Available at: http://
www.ped.med.utah.edu/. Access General Information and Follow
links to Infectious Diseases.
12. Rowley AH. Incomplete (atypical) Kawasaki disease. Pediatr
Infect Dis J. Jun 2002;21(6):563-565.
13. Bresee JS, Mast EE, Coleman PJ, et al. Hepatitis C virus
infection associated with administration of intravenous immune
globulin. A cohort study. JAMA. Nov 20 1996;276(19):1563-1567.
14. Berger A, Scharrer I, Doerr HW, Hess G, Weber B. Infection
with hepatitis G virus in immunoglobulin recipients. Lancet. Jan 18
1997;349(9046):207.
15. Lefrere JJ, Ravera N, Corbi C, Mariotti M, Loiseau P. Infection
with hepatitis G virus in immunoglobulin recipients. Lancet. Jan 18
1997;349(9046):206.
16. Matsubara T, Mason W, Kashani IA, Kligerman M, Burns JC.
Gastrointestinal hemorrhage complicating aspirin therapy in acute
Kawasaki disease. J Pediatr. May 1996;128(5 Pt 1):701-703.
17. Baker AL, Gauvreau K, Newburger JW, Sundel RP, Fulton DR,
Jenkins KJ. Physical and psychosocial health in children who
have had Kawasaki disease. Pediatrics. Mar 2003;111(3):579-
583.
18. Burns JC, Capparelli EV, Brown JA, Newburger JW, Glode MP.
Intravenous gamma-globulin treatment and retreatment in
Kawasaki disease. US/Canadian Kawasaki Syndrome Study
Group. Pediatr Infect Dis J. Dec 1998;17(12):1144-1148.
19. Dengler LD, Capparelli EV, Bastian JF, et al. Cerebrospinal
fluid profile in patients with acute Kawasaki disease. Pediatr Infect
Dis J. Jun 1998;17(6):478-481.
20. Quasney MW, Bronstein DE, Cantor RM, et al. Increased
frequency of alleles associated with elevated tumor necrosis
factor-alpha levels in children with Kawasaki disease. Pediatr Res.
May 2001;49(5):686-690.
21. Leung DY, Meissner HC, Shulman ST, et al. Prevalence of
superantigen-secreting bacteria in patients with Kawasaki
disease. J Pediatr. Jun 2002;140(6):742-746.
22. Shingadia D, O'Gorman M, Rowley AH, Shulman ST. Surface
and cytoplasmic immunoglobulin expression in circulating B-
lymphocytes in acute Kawasaki disease. Pediatr Res. Oct
2001;50(4):538-543.
23. Burns JC, Mason WH, Glode MP, et al. Clinical and
epidemiologic characteristics of patients referred for evaluation of
possible Kawasaki disease. United States Multicenter Kawasaki
Disease Study Group. J Pediatr. May 1991;118(5):680-686.